Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
19.99
+0.12 (0.60%)
At close: Mar 28, 2025, 4:00 PM
19.86
-0.13 (-0.65%)
After-hours: Mar 28, 2025, 4:54 PM EDT
Dianthus Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Dianthus Therapeutics stock have an average target of 54.33, with a low estimate of 36 and a high estimate of 84. The average target predicts an increase of 171.79% from the current stock price of 19.99.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Dianthus Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 3 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $36 | Buy | Reiterates | $36 | +80.09% | Mar 12, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $84 | Strong Buy | Reiterates | $84 | +320.21% | Mar 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +100.10% | Mar 12, 2025 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Dec 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +100.10% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
3.79M
from 6.24M
Decreased by -39.29%
Revenue Next Year
3.67M
from 3.79M
Decreased by -3.17%
EPS This Year
-3.47
from -2.55
EPS Next Year
-3.73
from -3.47
Revenue Forecast
| Revenue | 2025 | 2026 | 2028 | 2029 |
|---|---|---|---|---|
| High | 9.1M | 9.1M | 141.5M | |
| Avg | 3.8M | 3.7M | 31.8M | |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2028 | 2029 |
|---|---|---|---|---|
| High | 46.3% | 141.0% | 3,761.9% | |
| Avg | -39.3% | -3.2% | 767.1% | |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.63 | -3.06 | -2.69 | ||
| Avg | -3.47 | -3.73 | -4.21 | ||
| Low | -3.99 | -4.51 | -6.06 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.